Be a leading provider of diagnostics systems that:
Are less painful and invasive to patients Improve diagnostics accuracy of significant medical conditions Enhance the profitability of medical practices Automate data acquisition and electronic medical records.

Painless, efficient clinical diagnostics


SensiVida Medical Technologies, Inc. is a minimally invasive bio-medical diagnostic device company. Its proprietary optical Micro-systems based technology automates bio-sensing and data acquisition while minimizing patient discomfort. The company's platform technology addresses a number of disease state diagnostics - allergy testing, pain-free automated glucose monitoring without bio-fouling, blood coagulation testing (e.g. for Coumadin patients), TB testing and cholesterol monitoring. The company has been developing two products based on its platform technology. The initial focus is to commercialize a highly accurate, rapid, 2X productive, pain- free allergy test system in the US ($1.6B market growing at a compounded rate of 7%). Several prototypes have been made and proof-of-concept human clinical trial has been completed. The second product, based on the same technology is a unique portable glucose monitor ($8B market growing at a compounded rate of 8%). This highly differentiated device consists of a patch having multiple individually - addressable sensors that are activated in accordance to the patient's test schedule, automatically measuring the glucose level without bio-fouling, clogging or daily calibration. In addition, the company possesses a unique Molecular Optical Biopsy technology (Photonic "pill") that permits the diagnosis of cancerous or pre-cancerous tissue without a biopsy.


CEO Sarbadhikari, representing an experienced and successful corporate management team dedicated to excellence, said, "We are extremely excited by the prospects of being part of a new public company with a new capital structure, new name, new symbol, broad new platform technology with large market potential." We are a minimally-invasive diagnostic device company with proprietary, Microsystems-based technology that automates bio-sensing and data acquisition while minimizing patient discomfort. Our optical-digital "platform" technology addresses a number of multi-billion dollar market opportunities -disease-state diagnostics: allergy testing, pain-free automated glucose monitors without bio-fouling, blood coagulation testing, TB testing, and cholesterol monitoring. SensiVida has an exclusive worldwide license under nine pending patents. Several working prototypes of the allergy test system and proof-of- principle human clinical results have been accomplished. The product pipe line, based on the same technology "chassis", includes a portable glucose monitor. This device consists of a patch or chip having multiple, individually addressable sensors that are activated in accordance with the patient's test schedule, automatically recording the patient's glucose level without pain, bio-fouling or clogging.

David R. Smith has been appointed as Chairman of the new Board of Directors. Messrs. Kamal Sarbadhikari and Jose Mir are appointed as the President and CEO and the CTO of the Company, respectively.

Kamal Sarbadhikari is an entrepreneurial senior executive with 40 years of start-up and management of Fortune 1000 companies. Prior to SensiVida, he ran Bausch and Lomb's $520M surgical businesses. He was part of the original team responsible for commercializing soft-contact lenses, a $5B global business. As a VP of R&D at Bausch and Lomb, he was responsible for the development of the OTC contact lens solution business., He was also the co-founder of Eastman Kodak's consumer battery business and part of a small team that commercialized Kodak's first successful consumer digital "Home Imaging" initiative and the "Picture Maker" kiosk for retail photo-scanning and printing.

Jose Mir started his career at the Eastman Kodak Company, pioneering new technologies that enabled some of the world's earliest digital imaging products. He evangelized and co-founded a corporate worldwide innovation initiative that after five years was able to drive significant growth beyond Kodak's traditional product lines. Mr. Mir had P&L responsibilities for a $16M business that commercialized four radically new digital products- two of them won industry awards for technical excellence. After leaving Kodak, he started and led Infotonics Technology Center's Innovation initiative, responsible for founding two new start-ups. Most recently, he founded SensiVida Medical Systems Inc. and served as its President/CTO for three years. Mr. Mir is a prolific inventor, has won several professional awards, and has served on boards for companies and universities.

David Smith is a founding member of Infotonics Technology Center Inc. and served as its President, Chief Executive Officer and Chairman of the Board from 2002 to 2008. Mr. Smith also previously served as the Chairman of the Board for OIDA (Optoelectronic Industry Development Association). His professional memberships are the Institute of Electronics Engineers (IEEE Senior Member) and American Society for Quality. He began his Kodak career in 1965 as an electrical engineer. He has had many diverse assignments in Kodak Apparatus Division and Kodak Park Engineering with increasing levels of responsibility in design engineering, technology development, process improvement and systems engineering. In 1985 he was appointed Director of Automatic Machine Systems Technology, now known as Manufacturing Systems Technology Division. MSTD is a corporate technical resource that develops manufacturing process technology, designs high performance manufacturing systems and installs these systems in new and existing factories around the world. Effective June 1997, David R. Smith was then appointed Director, Production Systems Engineering & Technology Organization, and Eastman Kodak Research & Development. The organization concentrated on process R&D for discrete products, encompassing media converting, packaging and high volume equipment manufacturing. Mr. Smith remained the R&D Technical Director, Advanced Production & Commercialization Technology Platform until he retired. Mr. Smith has a MS in Electrical Engineering from University of Rochester and a BS in Electrical Engineering University of Massachusetts.

 

SensiVida Medical Technologies
77 Ridgeland Road
Henrietta, NY 14623
Phone: 585-413-9080

Currently Not Available

Safe Harbor disclaimer: Certain statements contained herein constitute forward-looking statements within the meaning of Section 27Aof the Securities Act and Section 21E of the Exchange Act. Such statements include, without limitation, statements regarding business and financing plans, business trends and future operating revenues and expenses. Although the company believes that the statements are reasonable, it can give no assurance that such expecta- tions will prove to be correct. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate and similar expressions, or which by their nature refer to future events. The company cautions investors that any forward-looking statements made by the company are not guarantees of future performance, and that the actual results may differ materially from those in the forward-looking statements as a result of vari- ous factors, including but not limited to, the company’s ability to continue its projected growth, or to be able to fully implement its business strategies.

This profile is not without bias, and is a paid release. investingnewsalerts.com has been compensated ten thousand dollars of free trading stock, for services provided including dissemination of company information in this release. investingnewsalerts.com holds no other shares of the stock.   investingnewsalerts.com may receive shares for extension of its services. Any shares will be disclosed at such time that investingnewsalerts.com is aware of a clients desire to extend the original services. investingnewsalerts.com may have received shares of a company profiled in this release prior to the dissemination of the information in this release. investingnewsalerts.com may immediately sell some or any shares in a profiled company held by investingnewsalerts.com and may have previously sold shares in a profiled company held by investingnewsalerts.com. investingnewsalerts.com's services for a company may cause the company's stock price to increase, in which event investornewsalerts.com would make a profit when it sells its stock in a company. In addition, investingnewsalerts.com's selling of a company's stock may have a negative effect on the market price of the stock.

Got question, found problem? - info@investingnewsalerts.com